Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization  Antonio La Marca,

Slides:



Advertisements
Similar presentations
Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T
Advertisements

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Longitudinal assessment of circulating insulin-like peptide 3 levels in healthy peripubertal girls  Casper P. Hagen, Ph.D., Mikkel G. Mieritz, M.D., John.
Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.
Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M
Noninvasive metabolomic profiling of embryo culture media using Raman and near- infrared spectroscopy correlates with reproductive potential of embryos.
Longitudinal assessment of circulating insulin-like peptide 3 levels in healthy peripubertal girls  Casper P. Hagen, Ph.D., Mikkel G. Mieritz, M.D., John.
Association of functional genetic variants of CTLA4 with reduced serum CTLA4 protein levels and increased risk of idiopathic recurrent miscarriages  Maneesh.
Association of insulin receptor genetic variants with polycystic ovary syndrome in a population of women from Central Europe  Felicia A. Hanzu, M.D.,
Age at menarche: a predictor of diminished ovarian function?
Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization.
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Infertility evaluation and treatment among women in the United States
Antimüllerian hormone levels and numbers and sizes of antral follicles in regularly menstruating women of reproductive age referenced to true ovulation.
Reporting in vitro fertilization cycles to the Society for Assisted Reproductive Technology database: where have all the cycles gone?  David Kulak, M.D.,
Mike Ripley, M. D. , F. R. C. S. C. , Andrea Lanes, M. Sc
Antimüllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause  Linlin Cui, M.D., Ph.D., Yingying.
Assisted reproductive technologies do not increase risk of abnormal methylation of PEG1/MEST in human early pregnancy loss  Hai-Yan Zheng, M.D., Xiao-Yun.
Gene-gene interactions and risk of recurrent miscarriages in carriers of endocrine gland–derived vascular endothelial growth factor and prokineticin receptor.
Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women  Carlos Iglesias, M.D., Manish Banker, M.D.,
Signe Altmäe, M. Sc. , Anneli Stavreus-Evers, Ph. D. , Jonatan R
A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization.
Orhan Bukulmez, M. D. , Qin Li, M. S. , Bruce R. Carr, M. D
Changes in serum anti-Müllerian hormone levels may predict damage to residual normal ovarian tissue after laparoscopic surgery for women with ovarian.
How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization  Robert L. Klitzman, M.D.  Fertility.
FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending.
Occurrence of postmenopausal-like acidic follicle-stimulating hormone (FSH) isoforms precedes the rise of FSH before menopause  Chris M.G. Thomas, Ph.D.,
Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with.
Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.
Genetic variants in the ETV5 gene in fertile and infertile men with nonobstructive azoospermia associated with Sertoli cell–only syndrome  Moira K. O'Bryan,
Age-associated alteration of oocyte-specific gene expression in polar bodies: potential markers of oocyte competence  Ze-Xu Jiao, M.D., Ph.D., Min Xu,
Single-nucleotide polymorphisms in the promoter region influence the expression of the human follicle-stimulating hormone receptor  Alain Wunsch, M.Sc.,
Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T
Robert F. Casper, M.D.  Fertility and Sterility 
Albert Hsu, M. D. , Margaret Arny, Ph. D. , Alexander B. Knee, M. S
Ala16Val SOD2 polymorphism is associated with higher pregnancy rates in in vitro fertilization cycles  José Ignacio Ruiz-Sanz, Ph.D., Igor Aurrekoetxea,
Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study  Frederic Mitri,
Links between age at menarche, antral follicle count, and body mass index in African American and European American women  Sonya M. Schuh, Ph.D., Julia.
HOXA10 mutations in congenital absence of uterus and vagina
Polycystic ovary morphology: age-based ultrasound criteria
A new approach to ovarian reserve testing
David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D. 
A modest but significant effect of CGB5 gene promoter polymorphisms in modulating the risk of recurrent miscarriage  Kristiina Rull, M.D., Ph.D., Ole.
What are patients doing with their mosaic embryos
Mitchell P. Rosen, M. D. , Erica Johnstone, M. D. , Charles E
Synchronization of ovarian stimulation with follicle wave emergence in patients undergoing in vitro fertilization with a prior suboptimal response: a.
Antonio La Marca, M. D. , Simone Giulini, M. D. , Giovanni Vito, M. D
Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating.
Birth outcomes after spontaneous or assisted conception among infertile Australian women aged 28 to 36 years: a prospective, population-based study  Danielle.
Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis.
Tolga B. Mesen, M. D. , Lamya Kacemi-Bourhim, M. D. , Paul B
Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis 
Fertility and Sterility
Effectiveness of highly purified human menopausal gonadotropin vs
Association study between single nucleotide polymorphisms in the VEGF gene and polycystic ovary syndrome  Eung-Ji Lee, M.Sc., Bermseok Oh, Ph.D., Jong-Young.
FSHB-211 and FSHR 2039 are associated with serum levels of follicle-stimulating hormone and antimüllerian hormone in healthy girls: a longitudinal cohort.
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
The menopausal transition
Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.
Genetic evaluation procedures at sperm banks in the United States
Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function  David H. Barad, M.D., M.S., Andrea Weghofer,
Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation 
Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories  Melissa C. Yih, M.D.,
Divergent effects of the 677C>T mutation of the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene on ovarian responsiveness and anti-Müllerian hormone.
Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D
Bárbara Oriol, M. D. , Ana Barrio, M. D. , Alberto Pacheco, Ph. D
Altered circulating levels of matrix metalloproteinases 2 and 9 and their inhibitors and effect of progesterone supplementation in women with endometriosis.
Sequence variation analysis of the prolactin receptor C-terminal region in women with premature ovarian failure  Anne Bachelot, M.D., Ph.D., Justine Bouilly,
Serum anti-müllerian hormone levels in women with secondary amenorrhea
Identification of novel polymorphisms in the nuclear protein genes and their relationship with human sperm protamine deficiency and severe male infertility 
Presentation transcript:

Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization  Antonio La Marca, M.D., Ph.D., Giovanna Sighinolfi, M.D., Cindy Argento, M.D., Valentina Grisendi, M.D., Livio Casarini, M.D., Annibale Volpe, M.D., Manuela Simoni, M.D.  Fertility and Sterility  Volume 99, Issue 4, Pages 970-978.e1 (March 2013) DOI: 10.1016/j.fertnstert.2013.01.086 Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Genetic variation in the FSH beta-subunit (FSHB) gene. FSHB gene transcribed regions are indicated by boxes, and translated sequences are denoted by gray areas. Common polymorphisms (minor allele frequency >10%) that form two major gene haplotypes are shown as circle-headed bars, and their positions are denoted relative to the FSHB transcription start site. The FSHB -211G/T promoter SNP is indicated by an asterisk. FSHB mutations identified in infertile patients are shown by triangles. (modified from reference [98] with permission). Fertility and Sterility 2013 99, 970-978.e1DOI: (10.1016/j.fertnstert.2013.01.086) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Schematic model of FSHR gene (A) and protein (B). The distribution of most common SNPs is shown. (modified from reference [27] with permission). Fertility and Sterility 2013 99, 970-978.e1DOI: (10.1016/j.fertnstert.2013.01.086) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Women (n = 421) were genotyped for FSHR 680 polymorphisms. There were no significant differences in serum AMH levels and AFC between the different polymorphisms. (modified from reference [33] with permission). Fertility and Sterility 2013 99, 970-978.e1DOI: (10.1016/j.fertnstert.2013.01.086) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 4 Basal FSH levels and ampules of FSH used in COS for patients with variants of the FSHR. In women using assisted reproductive technology, the distribution was 45% for the wild-type (Asn/Asn), 29% for the heterozygote (Asn/Ser), and 26% for the homozygote (Ser/Ser). Although peak E2 levels, numbers of preovulatory follicles, and numbers of retrieved oocytes were similar in the three groups, basal FSH levels were significantly higher for carriers of the Ser variant. Furthermore, both the heterozygotes and homozygotes required significantly more FSH during COS compared with the wild-type group (∗P<.05 vs. other groups). (modified from reference [106]). Fertility and Sterility 2013 99, 970-978.e1DOI: (10.1016/j.fertnstert.2013.01.086) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 1 Age of menopause (top) and duration of fertility (low) in 251 postmenopausal Italian women genotyped for FSHR gene polymorphism at codon 680. The box plots indicate the first and third quartiles, with the horizontal line representing the median; the error bars correspond to percentiles 10 and 90, and extreme values are represented by circles. (modified from reference [67] with permission). Fertility and Sterility 2013 99, 970-978.e1DOI: (10.1016/j.fertnstert.2013.01.086) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions